EP4121050A1 - Compositions polymorphes stables de bréquinar sodium et procédés d'utilisation et de fabrication de celles-ci - Google Patents

Compositions polymorphes stables de bréquinar sodium et procédés d'utilisation et de fabrication de celles-ci

Info

Publication number
EP4121050A1
EP4121050A1 EP21770978.1A EP21770978A EP4121050A1 EP 4121050 A1 EP4121050 A1 EP 4121050A1 EP 21770978 A EP21770978 A EP 21770978A EP 4121050 A1 EP4121050 A1 EP 4121050A1
Authority
EP
European Patent Office
Prior art keywords
brequinar
hours
sodium salt
cancer
brequinar sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21770978.1A
Other languages
German (de)
English (en)
Other versions
EP4121050A4 (fr
Inventor
Abdolsamad Tadayon
Ping Huang
Chaoyi DENG
Jinsuo YANG
Siyi Jiang
Qingqing LU
Lin Cui
Mo JIA
Xianjun You
David P. Hesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clear Creek Bio Inc
Original Assignee
Clear Creek Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clear Creek Bio Inc filed Critical Clear Creek Bio Inc
Publication of EP4121050A1 publication Critical patent/EP4121050A1/fr
Publication of EP4121050A4 publication Critical patent/EP4121050A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Definitions

  • the invention relates generally to pharmaceutical compositions that contain crystalline forms of brequinar sodium salt, methods of making such compositions, and methods of using such compositions to treat a condition in a subject.
  • Brequinar is a compound that acts as a potent and selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), an enzyme required for pyrimidine synthesis.
  • DHODH dihydroorotate dehydrogenase
  • the drug blocks synthesis of pyrimidine-based nucleotides in the body and so inhibits cell growth. Brequinar has been investigated for numerous different indications.
  • the invention recognizes that crystals of brequinar sodium salt exist in multiple polymorphic forms and that one of those forms, polymorphic form C, is most stable under ambient conditions. Therefore, the stable crystalline form of brequinar sodium salt described herein allows the drug to be formulated in pharmaceutical compositions (for example solid pharmaceutical compositions for oral administration) amenable to commercial production and distribution. Prior to the insight of this invention, manufacture of crystalline brequinar sodium salt was deemed too unpredictable for large-scale manufacture, such as for example manufacture of solid oral dosage forms (e.g., such as tablets and capsules).
  • the compositions of the invention overcome prior stability and consistency issues in the manufacturing process to provide the most stable form of brequinar sodium.
  • the polymorphic form of brequinar sodium salt described herein enables the manufacture and distribution of solid dosage forms that can be easily self- administered by patients.
  • the invention also provides methods of making crystals of polymorphic form C of brequinar sodium salt.
  • the invention also provides methods of using compositions containing polymorphic form C of brequinar sodium salt to treat various conditions.
  • the polymorphic form C of brequinar sodium salt can be formulated in any type of pharmaceutical formulation for any route of delivery.
  • the invention provides crystals containing polymorphic form C of brequinar sodium salt.
  • the polymorphic form C of may contain a brequinar sodium salt hydrate.
  • the invention provides pharmaceutical compositions containing a solid form of brequinar sodium salt, wherein at least 75% of the brequinar sodium salt is polymorphic form C.
  • the composition may contain a solid form of brequinar sodium salt in which at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the brequinar sodium salt is polymorphic form C.
  • the polymorphic form C of brequinar sodium salt may contain a brequinar sodium salt hydrate.
  • the composition may be formulated for administration via a particular route.
  • the composition may be formulated for oral, intravenous, enteral, parenteral, dermal, buccal, topical, transdermal, subcutaneous, nasal, or pulmonary administration.
  • the composition may be formulated for administration by injection or with or on an implantable medical device.
  • the invention provides methods of treating a condition in a subject by providing to a subject having the condition a pharmaceutical composition containing a brequinar sodium salt, wherein at least 75% of the brequinar sodium salt is polymorphic form C.
  • the method may include providing a composition that contains the brequinar sodium salt in which at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the brequinar sodium salt is polymorphic form C.
  • the polymorphic form C of brequinar sodium salt may contain a brequinar sodium salt hydrate.
  • compositions containing polymorphic form C of brequinar sodium salt may be administered in as any type of pharmaceutical composition suitable for any route of administration.
  • the composition may be provided orally, intravenously, enterally, parenterally, dermally, buccally, topically, transdermally, by injection, subcutaneously, nasally, pulmonarily, or with or on an implantable medical device.
  • compositions described herein may be used to treat any condition for brequinar has been associated with for us, such as cancer or viral infections or an autoimmune disorder.
  • the condition may be a viral infection.
  • the viral infection may include an adenovirus, coronavims, enterovirus, human metapneumovims, human parainfluenza vims, human respiratory syncytial virus, influenza virus, or rhinovirus.
  • the coronavims may be Middle East respiratory syndrome coronavims (MERS-CoV), severe acute respiratory syndrome coronavims (SARS-CoV), or severe acute respiratory syndrome coronavims 2 (SARS-CoV-2).
  • the influenza virus may be influenza A, influenza B, influenza C, or influenza D.
  • the influenza A virus may be a HINT, H3N2, N9N2, or H5N1 strain.
  • the infection may affect a particular tissue, organ, or system.
  • the infection may affect one or more of the alveoli, bronchi, bronchioles, larynx, lungs, nasal cavities, nose, pharynx, respiratory system, sinuses, and trachea.
  • the condition may be cancer.
  • the cancer may be acute lymphoblastic leukemia, acute myeloid leukemia, adult T cell leukemia/lymphoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, gastric cancer, glioblastoma, glioma, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, Merkel cell carcinoma, myeloma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, or uterine cancer.
  • the condition may be an autoimmune disorder.
  • the autoimmune disorder may be arthritis, hepatitis, chronic obstructive pulmonary disease, multiple sclerosis, or tendonitis.
  • the invention provides methods of making a crystal containing polymorphic form C of brequinar sodium salt, the methods including the steps of combining a solid form of brequinar acid, sodium hydroxide (NaOH), and a solvent to produce a solution and crystallizing brequinar sodium salt from the solution to produce a crystal comprising polymorphic form C of brequinar sodium salt.
  • the polymorphic form C of brequinar sodium salt may contain a brequinar sodium salt hydrate.
  • the solvent may contain isopropanol, water, or both.
  • the solvent may contain isopropanol and water in a defined ratio.
  • the solvent may contain isopropanol and water in a ratio of from about 90:10 to about 99:1, from about 92:8 to about 99:1, from about 95:5 to about 99:1, from about 96:4 to about 99:1, from about 97:3 to about 99:1, from about 90:10 to about 98:2, from about 92:8 to about 98:2, from about 95:5 to about 98:2, from about 96:4 to about 98:2, from about 97:3 to about 98:2, about 95:5, about 96:4, about 97:3, or about 98:2.
  • the solid form of brequinar acid may be combined with NaOH at a defined ratio.
  • the NaOH and solid form of brequinar acid may be combined at from about 0.25 to about 4.0, from about 0.5 to about 4.0, from about 0.75 to about 4.0, from about 1.0 to about 4.0, from about 0.25 to about 2.0, from about 0.5 to about 2.0, from about 0.75 to about 2.0, from about 1.0 to about 2.0, from about 0.25 to about 1.6, from about 0.5 to about 1.6, from about 0.75 to about 1.6, from about 1.0 to about 1.6, from about 0.25 to about 1.3, from about 0.5 to about 1.3, from about 0.75 to about 1.3, from about 1.0 to about 1.3, from about 0.25 to about 1.1, from about 0.5 to about 1.1, from about 0.75 to about 1.1, from about 1.0 to about 1.1, about 1.0, about 1.05, or about 1.1 molar equivalents.
  • the combining step may include incubating the combined brequinar acid, NaOH, and solvent at from about 60 °C to about 90 °C, from about 65 °C to about 90 °C, from about 70 °C to about 90 °C, from about 73 °C to about 90 °C, from about 60 °C to about 85 °C, from about 65 °C to about 85 °C, from about 70 °C to about 85 °C, from about 73 °C to about 85 °C, from about 60 °C to about 80 °C, from about 65 °C to about 80 °C, from about 70 °C to about 80 °C, from about 73 °C to about 80 °C, from about 60 °C to about 77 °C, from about 65 °C to about 77 °C, from about 70 °C to about 77 °C, from about 73 °C to about 77 °C, about 75 °C, or about
  • the combining step may include removing insoluble material from the solution or the combined brequinar acid, NaOH, and solvent. Insoluble material may be removed by filtration.
  • the combining step may include incubating the combined brequinar acid, NaOH, and solvent at from about 50 °C to about 70 °C, from about 55 °C to about 70 °C, from about 50 °C to about 65 °C, from about 55 °C to about 65 °C, about 55 °C, about 60 °C, or about 65 °C.
  • the combining step may include two or more of the aforementioned steps performed in a particular sequence.
  • the combining step may include two or more of the following steps performed in the following sequence: incubating the combined brequinar acid, NaOH, and solvent at a first temperature; removal of insoluble material; and incubating the combined brequinar, NaOH, and solvent at a second temperature, which may be lower than the first temperature.
  • the crystallizing step may include adding a seed crystal of polymorphic form C of brequinar sodium salt to the solution to produce a seeded mixture.
  • the crystallizing step may include incubating the seeded mixture at from about 15 °C to about 35 °C, from about 20 °C to about 35 °C, from about 15 °C to about 30 °C, from about 20 °C to about 30 °C, about 20 °C, about 25 °C, or about 30 °C.
  • the crystallizing step may include adding an alkane to the solution or seeded mixture to produce an alkane-containing mixture.
  • the alkane may be n-heptane.
  • the crystallizing step may include incubating the alkane-containing mixture for a defined period.
  • the crystallizing step may include incubating the alkane-containing mixture for from about 6 hours to about 24 hours.
  • the crystallizing step may include removing the solvent from the polymorphic form C of brequinar sodium salt. Removing the solvent may include filtering the polymorphic form C of brequinar sodium salt, drying the polymorphic form C of brequinar sodium salt, or both.
  • the crystallizing step may include two or more of the aforementioned steps performed in a particular sequence.
  • the crystallizing step may include two or more of the following steps performed in the following sequence: adding a seed crystal of polymorphic form C of brequinar sodium salt to the solution to produce a seeded mixture; incubating the seeded mixture at a defined temperature; adding an alkane to the solvent or the seeded mixture; incubating the alkane-containing mixture for a defined period; and removing the solvent from the polymorphic form C of brequinar sodium salt.
  • FIG. 1 is an X-ray powder diffraction (XRPD) pattern of brequinar sodium salt from batch PS04375-1-E-P4.
  • XRPD X-ray powder diffraction
  • FIG. 2 is a differential scanning calorimetry (DSC) thermogram of brequinar sodium salt from batch PS04375-1-E-P4.
  • FIG. 3 is a thermogravimetric analysis (TGA) thermogram of brequinar sodium salt from batch PS04375-1-E-P4.
  • FIG. 4 is an overlay of XRPD scans Patterns A-J of brequinar sodium salt from batch PS04375-1-E-P4.
  • FIG. 5 is a DSC thermogram of polymorphic form C of brequinar sodium salt from batch FR00514-2-SL-B9.
  • FIG. 6 is a TGA thermogram of polymorphic form C of brequinar sodium salt from batch FR00514-2-SL-B9.
  • FIG. 7 is a graph of a 'HNIVIR spectrum of polymorphic form C of brequinar sodium salt from batch FR00514-2-SL-B9.
  • FIG. 8 is an X-ray powder diffraction (XRPD) pattern of the polymorph C form of brequinar sodium salt prepared according to a method of the invention.
  • XRPD X-ray powder diffraction
  • Brequinar has been investigated as a therapeutic candidate to treat a variety of conditions. Although brequinar was identified more than 30 years ago, one limitation on its therapeutic utility has been the difficulty of formulating the compound for commercial scale manufacturing and production.
  • the invention overcomes that problem by identifying a crystal form of brequinar sodium salt that is stable and consistently reproducible in commercial manufacturing processes.
  • the invention recognizes that crystals of brequinar sodium salt may exist in a variety of polymorphic forms and that only one of those forms, polymorphic form C, is stable under ambient conditions.
  • the invention also provides methods of producing crystals containing the polymorphic form C of brequinar sodium salt.
  • the compositions and methods of the invention permit the production of stable solid forms of brequinar sodium that are suitable for large-scale manufacture, distribution, and storage.
  • the compositions herein can be formulated for any pharmaceutical composition for any route of administration.
  • the invention provides crystals of the polymorphic form C of brequinar sodium salt and pharmaceutical compositions containing such crystals.
  • Brequinar has the systematic name 6- fluoro-2-(2’-fluoro-l,r biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid and the following structure:
  • Brequinar is an inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme involved in pyrimidine synthesis.
  • DHODH converts dihydroorotate (DHO) to orotate, and inhibition of DHODH activity leads to accumulation of DHO.
  • DHODH dihydroorotate
  • cell membranes are permeable to DHO, inhibiting DHODH in the body results in elevated levels of DHO in the blood and other body fluids. Therefore, the activity of brequinar on its target can be monitored in vivo by analysis of DHO levels in body fluid samples.
  • Crystals of brequinar sodium salt exist in several different polymorphic forms.
  • the inventors have identified ten distinct X-ray powder diffraction (XRPD) patterns in crystals of brequinar sodium salt, Patterns A-J. Seven of the patterns, Patterns B, D, E, F, G, I and J, represent unstable polymorphic forms that spontaneously convert to polymorphic form C under conditions of ambient temperature and humidity. Pattern A represents a metastable form that also changes into other forms over time when stored at ambient conditions. In contrast, the polymorphic form C is stable under ambient conditions. Consequently, polymorphic form C of brequinar sodium salt is the most desirable for use in solid oral dosage formulations, such as tablets, because it retains its density and is not prone to swelling or shrinkage during manufacture, distribution, and storage of the drug.
  • XRPD X-ray powder diffraction
  • the crystals may contain brequinar sodium salt hydrate.
  • the composition may contain all or nearly all of the brequinar sodium salt in polymorphic form C.
  • the composition may contain a brequinar sodium salt in which at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the brequinar sodium salt is polymorphic form C.
  • the composition may be formulated for administration via any route.
  • the composition may be formulated for oral, intravenous, enteral, parenteral, dermal, buccal, topical, transdermal, subcutaneous, nasal, or pulmonarily administration.
  • the composition may be formulated for administration by injection or with or on an implantable medical device.
  • the composition for oral administration may be formulated as a caplet, capsule, pill, or tablet.
  • compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from sweetening agents, flavoring agents, coloring agents, and preserving agents, in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the compounds in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc.
  • inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate
  • granulating and disintegrating agents for example corn starch, or alginic acid
  • binding agents for example starch, gelatin or acacia
  • lubricating agents for example magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated, or they may be coated by known techniques to delay disintegration in the stomach and absorption lower down in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in U.S. Patents 4,256,108, 4,166,452 and 4,265,874, to form osmotic therapeutic tablets for control release. Preparation and administration of compounds is discussed in U.S. Pat. No. 6,214,841 and U.S. Pub. No. 2003/0232877, the contents of each of which are incorporated by reference herein.
  • Formulations for oral use may also be presented as hard gelatin capsules in which the compounds are mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin.
  • an inert solid diluent for example calcium carbonate, calcium phosphate or kaolin.
  • compositions may include other pharmaceutically acceptable carriers, such as sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; or excipients.
  • sugars such as lactose, glucose and sucrose
  • starches such as com starch and potato starch
  • cellulose, and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate
  • powdered tragacanth malt
  • gelatin gelatin
  • talc or excipients.
  • the pharmaceutically acceptable carrier may be an encapsulation coating.
  • the encapsulation coating may contain carrageenan, cellulose acetate phthalate, cellulose acetate succinate, cellulose acetate trimellitate, collagen, gelatin, hydroxypropyl methyl cellulose acetate, a methyl acrylate-methacrylic acid copolymer, polyvinyl acetate phthalate shellac, sodium alginate, starch, or zein.
  • the composition may be formulated for a non-oral route of administration.
  • the composition may be formulated for intravenous, enteral, parenteral, dermal, buccal, topical, transdermal, subcutaneous, nasal, or pulmonary administration.
  • the composition may be formulated for administration by injection or with or on an implantable medical device.
  • the composition may be formulated for direct non-oral administration.
  • the composition may be formulated to be mixed, dissolved, or converted to another format prior to administration.
  • brequinar may administered as a solution, suspension, emulsion, cream, paste, ointment, or any other format suitable for non-oral administration.
  • the composition may be formulated for single unit dosage.
  • the composition may be formulated for a divided dosage.
  • the invention provides methods of making a crystal containing polymorphic form C of brequinar sodium salt.
  • the methods include the steps combining a solid form of brequinar acid, sodium hydroxide (NaOH), and a solvent to produce a solution and crystallizing brequinar from the solution to produce a crystal of the polymorphic form C of brequinar sodium salt.
  • the methods may include additional steps, and the aforementioned steps may include steps or sub-steps within them.
  • the solvent may contain an organic solvent, water, or both.
  • the organic solvent may be an alcohol, such as ethanol or isopropanol.
  • the solvent may contain an alcohol, such as isopropanol, and water in a defined ratio.
  • the solvent may contain isopropanol and water in a ratio of from about 90:10 to about 99:1, from about 92:8 to about 99:1, from about 95:5 to about 99:1, from about 96:4 to about 99:1, from about 97:3 to about 99:1, from about 90:10 to about 98:2, from about 92:8 to about 98:2, from about 95:5 to about 98:2, from about 96:4 to about 98:2, from about 97:3 to about 98:2, about 95:5, about 96:4, about 97:3, or about 98:2.
  • a strong base such as NaOH
  • the solid form of brequinar acid may be combined with NaOH at a defined ratio.
  • the NaOH and solid form of brequinar may be combined at from about 0.25 to about 4.0, from about 0.5 to about 4.0, from about 0.75 to about 4.0, from about 1.0 to about 4.0, from about 0.25 to about 2.0, from about 0.5 to about 2.0, from about 0.75 to about 2.0, from about 1.0 to about 2.0, from about 0.25 to about 1.6, from about 0.5 to about 1.6, from about 0.75 to about 1.6, from about 1.0 to about 1.6, from about 0.25 to about 1.3, from about 0.5 to about 1.3, from about 0.75 to about 1.3, from about 1.0 to about 1.3, from about 0.25 to about 1.1, from about 0.5 to about 1.1, from about 0.75 to about 1.1, from about 1.0 to about 1.1,
  • the mixture may be heated, i.e., incubated at a first defined temperature.
  • the mixture may be incubated at from about 60 °C to about 90 °C, from about 65 °C to about 90 °C, from about 70 °C to about 90 °C, from about 73 °C to about 90 °C, from about 60 °C to about 85 °C, from about 65 °C to about 85 °C, from about 70 °C to about 85 °C, from about 73 °C to about 85 °C, from about 60 °C to about 80 °C, from about 65 °C to about 80 °C, from about 70 °C to about 80 °C, from about 73 °C to about 80 °C, from about 60 °C to about 77 °C, from about 65 °C to about 77 °C, from about 70 °C to about 77 °C, from about 70 °C to about 77 °C,
  • insoluble material may be removed by filtration.
  • the mixture or solution may be cooled, i.e., incubated at a second defined temperature that is lower than the first defined temperature.
  • the solution may be incubated at from about 50 °C to about 70 °C, from about 55 °C to about 70 °C, from about 50 °C to about 65 °C, from about 55 °C to about 65 °C, about 55 °C, about 60 °C, or about 65 °C.
  • the aforementioned steps involved in making the brequinar solution may be performed in a specific sequence.
  • two or more of the steps may be performed in the following sequence: mixing the solid form of brequinar acid and the solvent, optionally including the strong base, such as NaOH; heating the mixture by incubating it at a first temperature as described above; removing insoluble material from the mixture; and cooling the mixture by incubating it at a second temperature as described above.
  • the strong base such as NaOH
  • the crystallizing step may include adding a seed crystal of polymorphic form C of brequinar sodium salt to the solution to produce a seeded mixture.
  • the crystallizing step may include incubating the seeded mixture at a defined temperature.
  • the seeded mixture may be incubated at from about 15 °C to about 35 °C, from about 20 °C to about 35 °C, from about 15 °C to about 30 °C, from about 20 °C to about 30 °C, about 20 °C, about 25 °C, or about 30 °C.
  • the crystallizing step may include adding an agent that facilitates precipitation of the brequinar sodium salt.
  • the agent may be an organic compound, such as an alkane.
  • the alkane may be n-heptane.
  • the crystallizing step may include incubating the alkane-containing mixture for a defined period.
  • the crystallizing step may include incubating the alkane-containing mixture for from about 6 hours to about 24 hours.
  • the crystallizing step may include removing the solvent from the precipitated brequinar sodium salt. Removing the solvent may include filtering the brequinar sodium salt, drying the brequinar sodium salt, or both.
  • the crystallizing step may include two or more of the aforementioned steps performed in a particular sequence.
  • two or more of the steps may be performed in the following sequence: adding a seed crystal of polymorphic form C of brequinar sodium salt to the solution to produce a seeded mixture; incubating the seeded mixture at a defined temperature; adding an alkane to the seeded mixture; incubating the alkane-containing mixture for a defined period; and removing the solvent from the polymorphic form C of brequinar.
  • the invention provides methods of treating a condition in subject by providing to the subject a composition containing polymorphic form C of brequinar sodium salt.
  • the condition may be any disease, disorder, or condition for which brequinar provides a therapeutic benefit.
  • the condition may be a cancer.
  • the cancer may include a solid tumor or hematological tumor.
  • the cancer may be acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adult T cell leukemia/lymphoma (ATLL), bladder cancer, breast cancer, such as triple negative breast cancer (TNBC), cervical cancer, colorectal cancer, gastric cancer, glioblastoma, glioma, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, such as small cell lung cancer and non-small cell lung cancer, lymphoma, melanoma, Merkel cell carcinoma, myeloma, such as multiple myeloma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, or uterine cancer.
  • ALL acute lymphoblastic leukemia
  • AML acute myeloid leukemia
  • ATLL adult T cell leukemia/lymphoma
  • bladder cancer breast cancer, such as triple negative breast cancer (
  • DHODH dihydroorotate dehydrogenase
  • the condition may be or include one or more subtypes of AML.
  • AML cases are classified based on cytological, genetic, and other criteria, and AML treatment strategies vary depending on classification.
  • One AML classification system is provided by the World Health Organization (WHO).
  • the WHO classification system includes subtypes of AML provided in Table 1 and is described in Falini B, et al. (October 2010) "New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues" Discov Med. 10 (53): 281-92, PMID 21034669, the contents of which are incorporated herein by reference.
  • AML French- American-British
  • the FAB classification system includes the subtypes of AML provided in Table 2 and is described in Bennett JM, et al. (March 1976). "Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group" Br. J. Haematol. 33 (4); 451-8, doi: 10.1111/j.1365-2141.1976.tb03563.x. PMID 188440; and Bennett JM, et al. (June 1989) "Proposals for the classification of chronic (mature) B and T lymphoid leukemias.
  • the condition may be an inflammatory or autoimmune disorder.
  • the inflammatory or autoimmune disorder may be arthritis, hepatitis, chronic obstructive pulmonary disease, multiple sclerosis, or tendonitis.
  • the condition may be a psychiatric disorder.
  • the psychiatric disorder may be anxiety, stress, obsessive-compulsive disorder, depression, panic disorder, psychosis, addiction, alcoholism, attention deficit hyperactivity, agoraphobia, schizophrenia, or social phobia.
  • the condition may be an infection.
  • the infection may be a viral infection.
  • the vims infection may be infection with an adenovirus, coronavims, enterovirus, human metapneumovirus, human parainfluenza virus, human respiratory syncytial vims, influenza vims, or rhinovims.
  • the coronavims may be Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
  • the influenza virus may be influenza A, influenza B, influenza C, or influenza D.
  • the influenza A virus may be a HINT, H3N2, N9N2, or H5N1 strain.
  • the infection may affect a particular tissue, organ, or system.
  • the infection may affect one or more of the alveoli, bronchi, bronchioles, larynx, lungs, nasal cavities, nose, pharynx, respiratory system, sinuses, and trachea.
  • the condition may include a genetic mutation such as MYC amplification or PTEN loss that leads to increased dependence on the metabolic pathway, such as increased "addiction" to glutamine.
  • the condition may include or affect a sub-population of patients.
  • the patients may be pediatric, newborn, neonates, infants, children, adolescent, pre-teens, teenagers, adults, or elderly.
  • the patients may be in critical care, intensive care, neonatal intensive care, pediatric intensive care, coronary care, cardiothoracic care, surgical intensive care, medical intensive care, long-term intensive care, an operating room, an ambulance, a field hospital, or an out-of-hospital field setting.
  • Methods of treating a condition in a subject may include monitoring the level of a metabolite, such as DHO, in a sample obtained from the subject. Monitoring the level of a metabolite may include receiving information about the measured level of the metabolite. Monitoring the level of a metabolite may include measuring the metabolite.
  • a metabolite such as DHO
  • the metabolite is measured by mass spectrometry, optionally in combination with liquid chromatography.
  • Molecules may be ionized for mass spectrometry by any method known in the art, such as ambient ionization, chemical ionization (Cl), desorption electrospray ionization (DESI), electron impact (El), electrospray ionization (ESI), fast-atom bombardment (FAB), field ionization, laser ionization (LIMS), matrix-assisted laser desorption ionization (MALDI), paper spray ionization, plasma and glow discharge, plasma-desorption ionization (PD), resonance ionization (RIMS), secondary ionization (SIMS), spark source, or thermal ionization (TIMS).
  • ambient ionization chemical ionization
  • DESI desorption electrospray ionization
  • El electron impact
  • ESI electrospray ionization
  • FAB fast-atom bombardment
  • LIMS laser
  • a sample can be directly ionized without the need for use of a separation system.
  • mass spectrometry is performed in conjunction with a method for resolving and identifying ionic species. Suitable methods include chromatography, capillary electrophoresis-mass spectrometry, and ion mobility. Chromatographic methods include gas chromatography, liquid chromatography (LC), high-pressure liquid chromatography (HPLC), hydrophilic interaction chromatography (HILIC), ultra-performance liquid chromatography (UPLC), and reversed-phase liquid chromatography (RPLC). In a preferred embodiment, liquid chromatography-mass spectrometry (LC-MS) is used.
  • a sample may be obtained from any organ or tissue in the individual to be tested, provided that the sample is obtained in a liquid form or can be pre-treated to take a liquid form.
  • the sample may be a blood sample, a urine sample, a serum sample, a semen sample, a sputum sample, a lymphatic fluid sample, a cerebrospinal fluid sample, a plasma sample, a pus sample, an amniotic fluid sample, a bodily fluid sample, a stool sample, a biopsy sample, a needle aspiration biopsy sample, a swab sample, a mouthwash sample, a cancer sample, a tumor sample, a tissue sample, a cell sample, a synovial fluid sample, a phlegm sample, a saliva sample, a sweat sample, or a combination of such samples.
  • the sample may also be a solid or semi-solid sample, such as a tissue sample, feces sample, or stool sample, that has been treated to take a liquid form by, for example, homogenization, sonication, pipette trituration, cell lysis etc.
  • a sample is from plasma, serum, whole blood, or sputum.
  • the sample may be kept in a temperature-controlled environment to preserve the stability of the metabolite.
  • DHO is more stable at lower temperatures, and the increased stability facilitates analysis of this metabolite from samples.
  • samples may be stored at 4 °C, -20 °C, or -80 °C.
  • a sample is treated to remove cells or other biological particulates.
  • Methods for removing cells from a blood or other sample are well known in the art and may include e.g., centrifugation, sedimentation, ultrafiltration, immune selection, etc.
  • the sample may be obtained from an individual before or after administration to the subject of an agent that alters activity of a metabolic pathway, such as inhibitor of an enzyme in the pathway.
  • the sample may be obtained 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days or more before administration of an agent, or it may be obtained 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours, 24 hours, 36 hours, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days or more after administration of an agent.
  • Dosing regimens including determining dosing regimens based on levels of a metabolite
  • Methods of treating a condition may include providing to the subject a composition containing polymorphic form C of brequinar sodium salt according to a dosing regimen.
  • Compositions containing polymorphic form C of brequinar sodium salt in a solid form may be administered in their solid form, or they may be mixed, dissolved, or converted to another format prior to administration.
  • Such composition may be provided orally, intravenously, enterally, parenterally, dermally, buccally, topically, transdermally, by injection, subcutaneously, nasally, pulmonarily, or with or on an implantable medical device.
  • a dosing regimen may include a dosage and a schedule of administration.
  • a dosage of brequinar includes an amount of the drug.
  • the amount of brequinar may be expressed in absolute terms, e.g., mass of brequinar.
  • the amount of brequinar may be expressed in terms relating the amount to the subject, e.g., brequinar mass per subject mass, or brequinar mass per subject volume.
  • the amount of brequinar may be expressed in terms that indicate an effect of the drug, e.g., amount of brequinar that achieves a target concentration in a tissue or sample from the subject.
  • a dosage may include a period of time over which the amount is to be administered to the subject.
  • the dosage may include an amount of brequinar per unit of time.
  • the dosage may include a single dose, i.e., the entire amount may be provided at once.
  • the dosage may include multiple, e.g., 2, 3, 4, 6, or 8, doses that collectively achieve the entire amount of the dosage.
  • a schedule of administration may be described by the interval between doses, e.g., every 24 hours, every 48 hours, etc., or by the number doses administered during a given period, e.g., once per week, twice per week, etc.
  • the dosing regimen may include a schedule for administration of doses.
  • doses may be administered at regular intervals, such as every 24 hours, every 36 hours, every 48 hours, every 60 hours, every 72 hours, every 84 hours, every 96 hours, every 5 days, every 6 days, every week, every 2 weeks, every 3 weeks, or every 4 weeks.
  • doses may be administered according to a schedule that does not require precisely regular intervals. For example, doses may be administered once per week, twice per week, three times per week, four times per week, once per month, twice per month, three times per month, four times per month, five times per month, or six times per month.
  • the dosage of brequinar may be from about 10 mg to about 180 mg, from about 26 mg to about 180 mg, from about 51 mg to about 180 mg, from about 76 mg to about 180 mg, from about 101 mg to about 180 mg, from about 126 mg to about 180 mg, from about 151 mg to about 180 mg, from about 10 mg to about 150 mg, from about 26 mg to about 150 mg, from about 51 mg to about 150 mg, from about 76 mg to about 150 mg, from about 101 mg to about 150 mg, from about 126 mg to about 150 mg, from about 10 mg to about 125 mg, from about 26 mg to about 125 mg, from about 51 mg to about 125 mg, from about 76 mg to about 125 mg, from about 101 mg to about 125 mg, from about 10 mg to about 100 mg, from about 26 mg to about 100 mg, from about 51 mg to about 100 mg, from about 76 mg to about 100 mg, from about 10 mg to about 75 mg, from about 26 mg to about 75 mg, from about 51 mg to about 75 mg, from about
  • the dosage of brequinar may be from about 10 mg to about 4000 mg, from about 26 mg to about 4000 mg, from about 51 mg to about 4000 mg, from about 76 mg to about 4000 mg, from about 101 mg to about 4000 mg, from about 151 mg to about 4000 mg, from about 201 mg to about 4000 mg, from about 10 mg to about 2000 mg, from about 26 mg to about 2000 mg, from about 51 mg to about 2000 mg, from about 76 mg to about 2000 mg, from about 101 mg to about 2000 mg, from about 151 mg to about 2000 mg, from about 201 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 26 mg to about 1000 mg, from about 51 mg to about 1000 mg, from about 76 mg to about 1000 mg, from about 101 mg to about 1000 mg, from about 151 mg to about 1000 mg, from about 201 mg to about 1000 mg, from about 10 mg to about 500 mg, from about 26 mg to about 500 mg, from about 51 mg to about 500 mg, from about 76 mg to about
  • a dosing regimen for administration of brequinar, e.g., brequinar sodium, to a human subject may be as follows: 100 mg/m 2 , administered orally twice weekly; 125 mg/m 2 , administered orally twice weekly; 150 mg/m 2 , administered orally twice weekly; 200 mg/m 2 , administered orally twice weekly; 250 mg/m 2 , administered orally twice weekly; 275 mg/m 2 , administered orally twice weekly; 300 mg/m 2 , administered orally twice weekly; 350 mg/m 2 , administered orally twice weekly; 400 mg/m 2 , administered orally twice weekly; 425 mg/m 2 , administered orally twice weekly; 450 mg/m 2 , administered orally twice weekly; 500 mg/m 2 , administered orally twice weekly; 550 mg/m 2 , administered orally twice weekly; 600 mg/m 2 , administered orally twice weekly; 650 mg/m 2 , administered orally twice weekly; 700 mg/m 2 , administered orally
  • the dosage of brequinar may be an amount sufficient to maintain a concentration of brequinar in a lung of the subject of at least 0.01 pg/mL, at least 0.03 mg/mL, at least 0.1 mg/mL, at least 0.2 mg/mL, at least 0.3 mg/mL, at least 0.375 mg/mL, at least 0.4 mg/mL, at least 0.5 mg/mL, at least 0.6 mg/mL, at least 0.8 mg/mL, at least 1 mg/mL, at least 1.5 mg/mL, or at least 2 mg/mL for a 24-hour period.
  • a dosing regimen may contain a single dosage.
  • a dosing regimen may contain multiple dosages.
  • a dosing regimen may include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more dosages.
  • a dosing regimen may include multiple dosages provided consecutively.
  • a dosage may include a defined amount of brequinar provided over a defined period, e.g., one day or 24 hours, and the dosing regimen may include dosages provided in two or more consecutive periods, e.g., days or 24-hour periods.
  • each dosage may be the same, i.e., each includes the same amount of brequinar.
  • dosing regimens may include dosages that are not all the same.
  • the dosing regimen includes multiple consecutive dosages in which the first one, two, three, or four dosages are higher than subsequent dosages.
  • the dosing regimen includes multiple consecutive dosages in which the first the first one, two, three, or four dosages are lower than subsequent dosages.
  • the subsequent dosages may all the same, or they may differ from each other as well.
  • the dosing regimen may include any of the following sequences of dosages: alternation between high and low dosages; stepwise decreases or increases in individual dosages; stepwise decreases or increases in which one or more steps include two or more dosages that are the same; and patterns in which one or more of the aforementioned sequences is repeated or interspersed another aforementioned sequence.
  • Each dosage may independently be selected from any of the dosages described above.
  • the first dosage may be 100 mg
  • the subsequent dosages may be 25 mg, 50 mg, or 75 mg.
  • the dosing regimen may include a dosage-free period in which the subject does not receive brequinar or a pharmaceutically acceptable salt thereof.
  • the dosage-free period may be at least 12 hours, at least 24 hours, at least 36 hours, at least 48 hours, at least 60 hours, at least 72 hours, at least 5 days, at least 7 days, at least 10 days, at least 14 days, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, about 5 days, about 7 days, about 10 days, or about 14 days.
  • the dosage-free period may follow a dosage.
  • the dosage-free period may follow multiple dosages provided over consecutive 24-hour periods.
  • the dosage-free period may follow multiple dosages provided over 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 consecutive 24-hour periods.
  • the method may include determining a dosing regimen for a subject.
  • the dosing regimen may be determined by comparing a measured level of a metabolite, e.g., DHO, in a sample obtained from a subject to a reference that provides an association between the measured level and a recommended dosage adjustment of brequinar.
  • the reference may provide a relationship between administration of the brequinar composition and levels of the metabolite in the subject. The relationship can be empirically determined from a known dose and time of administration of brequinar and measured levels of the metabolite at one or more subsequent time points.
  • the reference may include a relationship between measured levels of brequinar or a metabolic product of brequinar and measured levels of the metabolite.
  • a dosing regimen may then be determined.
  • the dosing regimen may include a dosage of brequinar, a time for administration of the dosage, or both.
  • the dosing regimen may be determined de novo, or it may comprise an adjustment to a previous dosing regimen, such as an adjustment in the dosage, the interval between administration of dosages, or both.
  • the dosing regimen is designed to deliver brequinar to the subject in an amount that achieves a therapeutic effect.
  • the therapeutic effect may be a sign or symptom of a disease, disorder, or condition.
  • the therapeutic effect may be inhibition of DHODH, or it may be a change in an indicator of inhibition of DHODH.
  • the indicator may be a metabolite, such as DHO, and the therapeutic effect may be an increase or decrease in levels of the metabolite.
  • the therapeutic effect may be a decrease in number of cancer cells, a decrease in proliferation of cancer cells, an increase in differentiation of pre-cancerous cells, such as myeloblasts, complete remission of cancer, complete remission with incomplete hematologic recovery, morphologic leukemia-free stat, or partial remission. Increased differentiation of myeloblasts may be assessed by one or more of expression of CD 14, expression of CD1 lb, nuclear morphology, and cytoplasmic granules.
  • the dosing regimen may ensure that levels of a metabolite, such as DHO, are raised or maintained at a minimum threshold required to achieve a certain effect.
  • the dosing regimen may raise or maintain levels of the metabolite above a threshold level in the subject for a certain time period.
  • the time period may include a minimum, a maximum, or both.
  • the dosing regimen may raise or maintain levels of the metabolite above the threshold level for at least 6 hours, 12, hours, 24 hours, at least 48 hours, at least 60 hours, at least 72 hours, at least 84 hours, at least 96 hours, at least 5 days, at least 6 days, at least 7 days, at least 10 days, at least 2 weeks, or more.
  • the dosing regimen may raise or maintain levels of the metabolite above the threshold level for not more than 24 hours, not more than 36 hours, not more than 48 hours, not more than 60 hours, not more than 72 hours, not more than 84 hours, not more than 96 hours, not more than 5 days, not more than 6 days, not more than 7 days, not more than 10 days, or not more than 2 weeks.
  • the dosing regimen may raise or maintain levels of the metabolite above the threshold level for at least 72 hours but not more than 96 hours, for at least 72 hours but not more than 5 days, for at least 72 hours but not more than 6 days, for at least 72 hours but not more than 7 days, for at least 96 hours but not more than 7 days.
  • the dosing regimen may ensure that levels of a metabolite, such as DHO, do not exceed or are maintained below a maximum threshold that is associated with toxicity. Levels of the metabolite above a maximum threshold may indicate that brequinar is causing or is likely to cause an adverse event in the subject.
  • adverse events include abdominal pain, anemia, anorexia, blood disorders, constipation, diarrhea, dyspepsia, fatigue, fever, granulocytopenia, headache, infection, leukopenia, mucositis, nausea, pain at the injection site, phlebitis, photosensitivity, rash, somnolence, stomatitis, thrombocytopenia, and vomiting.
  • the dosing regimen may include a time point for administration of one or more subsequent doses to raise or maintain levels of the metabolite, such as DHO, above a threshold level for a certain time period.
  • the time point for administration of a subsequent dose may be relative to an earlier time point.
  • the time point for administration of a subsequent dose may be relative to a time point when a previous dose was administered or a time point when a sample was obtained from a subject.
  • the dosing regimen may include a schedule for administration of doses.
  • doses may be administered at regular intervals, such as every 24 hours, every 36 hours, every 48 hours, every 60 hours, every 72 hours, every 84 hours, every 96 hours, every 5 days, every 6 days, every week, every 2 weeks, every 3 weeks, or every 4 weeks.
  • doses may be administered according to a schedule that does not require precisely regular intervals. For example, doses may be administered once per week, twice per week, three times per week, four times per week, once per month, twice per month, three times per month, four times per month, five times per month, or six times per month.
  • a dosing regimen for administration of brequinar, e.g., brequinar sodium, to a human subject may be as follows: 100 mg/m 2 , administered intravenously twice weekly; 125 mg/m 2 , administered intravenously twice weekly; 150 mg/m 2 , administered intravenously twice weekly; 200 mg/m 2 , administered intravenously twice weekly; 250 mg/m 2 , administered intravenously twice weekly; 275 mg/m 2 , administered intravenously twice weekly; 300 mg/m 2 , administered intravenously twice weekly; 350 mg/m 2 , administered intravenously twice weekly; 400 mg/m 2 , administered intravenously twice weekly; 425 mg/m 2 , administered intravenously twice weekly; 450 mg/m 2 , administered intravenously twice weekly; 500 mg/m 2 , administered intravenously twice weekly; 550 mg/m 2 , administered intravenously twice weekly; 600 mg/m 2 , administered intravenously twice weekly; 650 mg/m 2 , administered intra
  • Minimum and maximum threshold levels of a metabolite depend on a variety of factors, such as the metabolites and type of sample. Minimum and maximum threshold levels may be expressed in absolute terms, e.g., in units of concentration, or in relative terms, e.g., in ratios relative to a baseline or reference value. For example, the minimum threshold (below which a patient may receive a dose increase or additional dose) could also be calculated in terms of increase from a pre-treatment DHO level or baseline level.
  • Minimum threshold levels of DHO or orotate in a human plasma sample may be about 0 ng/ml, about 10 ng/mL, about 20 ng/mL, about 50 ng/mL, about 100 ng/mL, about 150 ng/mL, about 200 ng/ruL, about 250 ng/ruL, about 300 ng/ruL, about 350 ng/ruL, about 400 ng/ruL, about 450 ng/ruL, about 500 ng/ruL, about 550 ng/ruL, about 600 ng/ruL, about 650 ng/ruL, about 700 ng/ruL, about 750 ng/ruL, about 800 ng/ruL, about 850 ng/ruL, about 900 ng/ruL, about 950 ng/ruL, about 1000 ng/ruL, about 1250 ng/ml, about 1500 ng/ml, about 1750 ng/ml, about
  • Maximum threshold levels of DHO or orotate in a human plasma sample may be about 50 ng/ruL, about 100 ng/ruL, about 150 ng/ruL, about 200 ng/ruL, about 250 ng/ruL, about 300 ng/ruL, about 350 ng/ruL, about 400 ng/ruL, about 450 ng/ruL, about 500 ng/ruL, about 550 ng/ruL, about 600 ng/ruL, about 650 ng/ruL, about 700 ng/ruL, about 750 ng/ruL, about 800 ng/ruL, about 850 ng/ruL, about 900 ng/ruL, about 950 ng/ruL, about 1000 ng/ruL, about 1250 ng/ml, about 1500 ng/ml, about 1750 ng/ml, about 2000 ng/ml, about 2500 ng/ml, about 3000 ng/
  • the minimum threshold of DHO or orotate may be about 1.5 times the baseline level, about 2 times the baseline level, about 2.5 times the baseline level, about 3 times the baseline level, about 4 times the baseline level, about 5 times the baseline level, about 10 times the baseline level, about 20 times the baseline level, about 50 times the baseline level, about 100 times the baseline level, about 200 times the baseline level, about 500 times the baseline level, about 1000 times the baseline level, about 2000 times the baseline level, or about 5000 times the baseline level.
  • the minimum threshold may include any ratio that falls between those recited above. Thus, the minimum threshold may be any ratio between 1.5 times the baseline level and 5000 times the baseline level.
  • the maximum threshold of DHO or orotate may be about 2 times the baseline level, about 2.5 times the baseline level, about 3 times the baseline level, about 4 times the baseline level, about 5 times the baseline level, about 10 times the baseline level, about 20 times the baseline level, about 50 times the baseline level, about 100 times the baseline level, about 200 times the baseline level, about 500 times the baseline level, about 1000 times the baseline level, about 2000 times the baseline level, about 5000 times the baseline level, or about 10,000 times the baseline level.
  • the maximum threshold may include any ratio that falls between those recited above. Thus, the maximum threshold may be any ratio between 2 times the baseline level and 10,000 times the baseline level.
  • Dosage of brequinar also depends on factors such as the type of subject and route of administration.
  • the dosage may fall within a range for a given type of subject and route of administration, or the dosage may adjusted by a specified amount for a given type of subject and route of administration.
  • dosage of brequinar for oral or intravenous administration to a subject may be about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 7.5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 50 mg/kg, about 75 mg/kg, or about 100 mg/kg.
  • Dosage of brequinar for oral or intravenous administration to a subject may be adjusted by about 1 mg/kg, about 2 mg/kg, about 5 mg/kg, about 7.5 mg/kg, about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, or about 50 mg/kg.
  • Dosage of brequinar for oral or intravenous administration to an animal subject, such as a human or mouse, may be about 50 mg/m 2 , about 100 mg/m 2 , about 200 mg/m 2 , about 300 mg/m 2 , about 350 mg/m 2 , about 400 mg/m 2 , about 500 mg/m 2 , about 600 mg/m 2 , about 700 mg/m 2 , about 750 mg/m 2 , about 800 mg/m 2 , or about 1000 mg/m 2 .
  • Dosage of brequinar for oral or intravenous administration to an animal subject, such as a human or mouse, may be adjusted by about 50 mg/m 2 , about 100 mg/m 2 , about 200 mg/m 2 , about 300 mg/m 2 , about 350 mg/m 2 , or about 400 mg/m 2 .
  • Methods may include determining whether the level of the metabolite is within a threshold range (e.g., above a minimal threshold and/or below a potential toxicity threshold) that warrants dosing, and/or that warrants dosing at a particular level or in a particular amount.
  • the methods may include providing at least one dose of brequinar to a subject whose plasma metabolite level has been determined and is below a pre-determined threshold (e.g., a pre-determined potential toxicity threshold and/or a pre-determined potential efficacy threshold).
  • a pre-determined threshold e.g., a pre-determined potential toxicity threshold and/or a pre-determined potential efficacy threshold.
  • the predetermined threshold reflects percent inhibition of DHODH in the subject relative to a baseline determined for the subject.
  • the baseline may be determined by an assay.
  • brequinar In order to maintain inhibition of DHODH at an effective threshold, multiple doses of brequinar may be administered to the subject. Dosing of brequinar may occur at different times and in different amounts.
  • the present disclosure encompasses those methods that can maintain inhibition of the target enzyme at a consistent level at or above the efficacy threshold throughout the course of treatment.
  • the amount of inhibition of DHODH is measured by the amount of metabolite in the plasma of a subject.
  • the method may comprise a step of re-determining the subject’s plasma metabolite level after administration of at least one dose.
  • the subject’s plasma metabolite level is re-determined after each dose.
  • the method may comprise administering at least one further dose of brequinar after the subject’s plasma metabolite level has been determined again (e.g., after administering a first or previous dose) to be below the pre-determined threshold. If the subject’s plasma metabolite level is determined to be above a pre-determined threshold, dosing can be discontinued. Thus, no further dose of brequinar is administered until the subject’s plasma metabolite level has been determined to again be below a pre-determined threshold.
  • the methods may include administering brequinar to a subject at a dosage level at or near a cell-lethal level. Such dosage may be supplemented with a later dose at a reduced level, or by discontinuing of dosing.
  • the method may include administering a plurality of doses of brequinar according to a regimen characterized by at least first and second phases, wherein the first phase involves administration of at least one bolus dose of brequinar at a cell-lethal level, and the second phase involves either administration of at least one dose that is lower than the bolus dose or absence of administration of brequinar.
  • brequinar is not administered during a second phase.
  • a second phase involves administration of uridine rescue therapy.
  • a bolus dose is or comprises a cell lethal dose.
  • a cell lethal dose is an amount of brequinar that is sufficient to cause apoptosis in normal (e.g., non- cancerous) cells in addition to target cells (e.g., cancer cells).
  • the first phase and the second phase each comprise administering brequinar. In some embodiments, the first phase and the second phase are at different times. In some embodiments, the first phase and the second phase are on different days. In some embodiments, the first phase lasts for a period of time that is less than four days. In some embodiments, the first phase comprises administering brequinar, followed by a period of time in which no brequinar is administered. In some embodiments, the period of time in which no brequinar is administered is 3 to 7 days after the dose during the first phase. In some embodiments, the first phase comprises administering more than one dose.
  • brequinar is administered during a second phase. In some embodiments, brequinar is administered sub-cell-lethal levels during the second phase. In some embodiments, the first phase is repeated after the second phase. In some embodiments, both the first and second phases are repeated.
  • the present disclosure provides a method of administering brequinar to a subject in need thereof, according to a multi-phase protocol comprising a first phase in which at least one dose of brequinar is administered to the subject and a second phase in which at least one dose of brequinar is administered to the subject, wherein one or more doses administered in the second phase differs in amount and/or timing relative to other doses in its phase as compared with the dose(s) administered in the first phase.
  • the level of a metabolite is determined in a sample from the subject between the first and second phases.
  • the sample is a plasma sample.
  • the timing or amount of at least one dose administered after the metabolite level is determined or differs from that of at least one dose administered before the metabolite level was determined.
  • the amount of brequinar that is administered to the patient is adjusted in view of the metabolite level in the subject’s plasma.
  • a first dose is administered in the first phase.
  • metabolite level is determined at a period of time after administration of the first dose.
  • the amount of brequinar administered in a second or subsequent dose is increased and/or the interval between doses is reduced.
  • the amount of brequinar administered may be increased, for example, by 100 mg/m 2 .
  • the amount of brequinar administered in a second or subsequent dose is increased by 150 mg/m 2 .
  • the amount of brequinar administered in a second or subsequent dose is increased by 200 mg/m 2 .
  • the amount of brequinar administered may be increased by an adjustment amount determined based on change in metabolite levels observed between prior doses of different amounts administered to the subject.
  • the amount of brequinar administered in a second or subsequent dose is the same as the amount administered in the first or previous dose and/or the interval between doses is the same.
  • the amount of brequinar in a second or subsequent dose is decreased and/or the interval between doses is increased.
  • the amount of brequinar administered may be decreased, for example, by 50 mg/m 2 .
  • the amount of brequinar in a second or subsequent dose is decreased by 75 mg/m 2 .
  • the amount of brequinar in a second or subsequent dose is decreased by 100 mg/m 2 .
  • the amount of brequinar administered may be decreased by an adjustment amount determined based on change in metabolite levels observed between prior doses of different amounts administered to the subject.
  • the present disclosure provides a method of administering a later dose of brequinar to a patient who has previously received an earlier dose of brequinar, wherein the patient has had a level of metabolite assessed subsequent to administration of the earlier dose, and wherein the later dose is different than the earlier dose.
  • the later dose may be different from the earlier dose in amount of brequinar included in the dose, time interval relative to an immediately prior or immediately subsequent dose, or combinations thereof.
  • the amount of brequinar in the later dose may be less than that in the earlier dose.
  • the method may include administering multiple dose of brequinar, separated from one another by a time period that is longer than 2 days and shorter than 8 days.
  • the time period may be about 3 days.
  • the metabolite level is determined in a sample from the subject before each dose is administered, and dosing is delayed or skipped if the determined metabolite level is above a pre-determined threshold.
  • the metabolite level may be determined about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, about 84 hours, or about 96 hours after administration of brequinar.
  • the method may include administering brequinar according to a regimen approved in a trial in which a level of metabolite was measured in a patient between doses of brequinar.
  • the regimen may include multiple doses whose amount and timing were determined in the trial to maintain the metabolite level within a range determined to indicate a degree of target enzyme inhibition below a toxic threshold and above a minimum threshold.
  • the regimen may include determining the metabolite level in the subject after administration of one or more doses of brequinar.
  • the regimen includes a dosing cycle in which an established pattern of doses is administered over a first period of time. In some embodiments, the regimen comprises a plurality of the dosing cycles. In some embodiments, the regimen includes a rest period during which brequinar is not administered between the cycles.
  • Methods of treating a condition in subject may entail the use of combination therapies that include a composition containing polymorphic form C of brequinar sodium salt and a second agent.
  • Combination therapies may be used to treat any of the conditions described above, and the choice of second agent depends on the condition being treated.
  • the second agent may target a signaling pathway.
  • the second agent may target a mitogen-activated protein kinase pathway, AKT pathway, or phosphoinositide 3-kinase pathway.
  • the second agent may target one or more effectors in a signaling pathway.
  • the second agent may target a pathway that includes p38, enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2), E12/E47, epidermal growth factor receptor (EGFR), FOXC2, Hippo, kallikrein-related peptidase 6 (KLK6), neuropilin-2 (NRP2), polo-like kinase 1 (PLK1), polycomb group PcG (PRC2), Raf, sex determining region Y-box 2 (SOX2), SNAI1, SNAI2, transforming growth factor beta (TGF-b), TWIST1, and yes-associated protein 1 (YAP1), ZEB1, and/or ZEB2.
  • EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit
  • E12/E47 epidermal growth factor receptor
  • FOXC2 Hippo
  • KLK6 kallikrein-related peptidase 6
  • NBP2 neuropilin-2
  • PLK1 polo-
  • the second agent may be an inhibitor of p38.
  • the p38 inhibitor may be AMG-548, asiatic acid, BIRB-796, BMS-582949, doramapimod, LY- 2228820, pamapimod, PH-797804, SB-202190, SB-203580, SB-239063, SCIO-323, SCIO-469, SD-169, SKF-86002, TAK-715, VX-702, or VX-745.
  • Other p38 inhibitors are described in, for example, U.S. Pat. Nos.
  • the second agent may be an antiviral agent.
  • the second agent may be a direct-acting antiviral agent, such as an agent that interferes with the function of a viral protein or enzyme.
  • the antiviral agent may be a SC- like main protease inhibitor, eIF4E inhibitor, helicase inhibitor, inhibitor of a viral structural protein, inhibitor of a virulence factor, inosine monophosphate dehydrogenase (IMPDH) inhibitor, interferon, papain-like proteinase inhibitor, protease inhibitor, or RNA-dependent RNA polymerase inhibitor.
  • the eIF4E inhibitor may be ribavirin.
  • the IMPDH inhibitor may be AS2643361, EICAR, FF-10501, mizoribine, mycophenolic acid, mycophenolate mofetil, ribavirin, selenazofurin, SM-108, taribavirin, tiazofurin, VX-148, VX-497, or VX-944.
  • the interferon may be peginterferon alpha-2a or peginterferon alpha-2b.
  • the protease inhibitor may be lopinavir, ritonavir, or a combination thereof.
  • the RNA-dependent RNA polymerase inhibitor may be AT-511, AT-527, AT-9010, beclabuvir, dasabuvir, deleobuvir, favipiravir, filibuvir, radalbuvir, remdesivir, setrobuvir, or sofosbuvir.
  • the virulence factor may be Nspl, Nsp3c, or ORF7a.
  • the second agent may be an anti-inflammatory agent.
  • Anti-inflammatory agents include corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).
  • anti-inflammatory agents include acematricin, acetate, aloe vera extracts, alpha- methyl dexamethasone, amcinafide, arnica flower, asprin, beclamethasone dipropionate, benorylate, benoxaprofen, betamethasone and its esters, chloroprednisone, chloroprednisone acetate, clescinolone, clidanac, clobetasol valerate, clocortelone, comfrey root, desonide, desoxycorticosterone acetate, desoxymethasone, dexamethasone, dexamethasone phosphate, dichlorisone, dichlorisone, diclofenac, di-florasone diacetate, diflucortolone and its derivatives, diflupre
  • meclofenamate sodium meclofenamate
  • medrysone mefenamic acid derivatives (e.g. N-(2,3- xyl-yl) anthranilic acid), meprednisone, methylprednisolone, naproxen, oxicams (e.g.
  • piroxicam and isoxicam oxyphenbutazone, paramethasone, phenylbutazone, prednisolone, prednisone, propionic acid esters such as ibuprofen, pyrazolidinediones, such as feprazone,, safaprin, salicylic acid derivatives, sulfinpyrazone, sulindac, suprofen, tolmetin, triamcinolone acetonide, trimethasone, trisilate, willow bark, and zomepirac.
  • Combination therapies may include multiple periods in which different agents or different combinations of agents are provided to the subject. Different agents or different combinations of agents may be provided concurrently, sequentially, in overlapping periods, in temporally separated periods, or in any other manner known to one of ordinary skill in the art. Exemplary temporal regimens for administering combination therapies are provided below.
  • combination therapy may include a first period and a second period that follows the first period, the periods being as follows: a first period during which a first agent but not a second agent is provided to the subject and a second period during which the second agent but not the first agent is provided to the subject; a first period during which a first agent and a second agent are provided to the subject and a second period during which the second agent but not the first agent is provided to the subject; a first period during which a first agent but not a second agent is provided to the subject and a second period during which the first agent and the second agent are provided to the subject; and a first period during which first combination of agents is provided to the subject and a second period during which a second, different combination of agents is provided to the subject.
  • brequinar or a pharmaceutically acceptable salt thereof is provided to the subject during a first period, and an anti-inflammatory agent is provided to the subject during a second period that follows the first period. Brequinar or a pharmaceutically acceptable salt thereof may be withheld from the subject during the second period. The anti-inflammatory may or may not be provided during the first period. Brequinar or a pharmaceutically acceptable salt thereof may be provided during the first period according to a dosing regimen, such as any of those described above.
  • a combination therapy may include providing brequinar or a pharmaceutically acceptable salt thereof in the same formulation as a second agent, such as an antiviral agent or anti-inflammatory agent.
  • brequinar or a pharmaceutically acceptable salt thereof and dexamethasone are provided in the same formulation.
  • a combination therapy may include providing brequinar or a pharmaceutically acceptable salt thereof and a second agent, such as an antiviral agent or anti inflammatory agent, in separate formulations.
  • a second agent such as an antiviral agent or anti inflammatory agent
  • brequinar or a pharmaceutically acceptable salt thereof and dexamethasone are provided in separate formulations.
  • BRQ brequinar
  • FIG. 1 is an X-ray powder diffraction (XRPD) pattern of brequinar sodium salt from batch PS04375-1-E-P4.
  • FIG. 2 is a differential scanning calorimetry (DSC) thermogram of brequinar sodium salt from batch PS04375-1-E-P4.
  • FIG. 3 is a thermogravimetric analysis (TGA) thermogram of brequinar sodium salt from batch PS04375-1-E-P4.
  • Pattern A research batch brequinar sodium salt
  • Ten hydrates have been identified: Patterns A, B, C, D, E, F, G, H, I and J.
  • FIG. 4 is an overlay of XRPD scans Patterns A-J of brequinar sodium salt from batch PS04375-1-E-P4.
  • the polymorphic forms of brequinar are summarized in Table 3.
  • Patterns B, D, E, F, G, I and J are unstable and convert into Pattern C under ambient condition.
  • Pattern A the starting material, is also a metastable form, and changes into different polymorphs occurred during polymorphic screening study.
  • Pattern C remains the same under vacuum drying condition of 50 °C for 18 h. The data provided here demonstrated that Pattern C is a desired form for commercial development due to its stability during manufacturing and storage.
  • FIG. 5 is a DSC thermogram of polymorphic form C of brequinar sodium salt from batch
  • FIG. 6 is a TGA thermogram of polymorphic form C of brequinar sodium salt from batch FR00514-2-SL-B9.
  • FIG. 7 is a graph of a 'HNIVIR spectrum of polymorphic form C of brequinar sodium salt from batch FR00514-2-SL-B9.
  • 6-Flouro-2-(2’-fluoro-l,l’-biphenyl-4-yl)-3-methyl-4- quinolinecarboxylic acid sodium salt was carried out by dissolving 6-Flouro-2-(2’-fluoro-l,l’- biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic acid (1.0 eq) in a mixture of isopropanol/water in a ratios of 95/5 to 98/2 with the most desired ratio being 97/3.
  • Sodium hydroxide (1.05 eq) was added and the mixture warmed to a temperature of 70-80 °C until everything was dissolved. The most desired temperature for dissolution is 73-77 °C.
  • the mixture was cooled to 55-65 °C and a seed crystal of 6-Flouro-2-(2’-fluoro-l,l’-biphenyl-4-yl)-3-methyl-4-quinolinecarboxylic sodium salt added, cooled to 20-30 °C and n-heptane added. The most desired temperature for addition of n-heptane is 23-27 °C.
  • the mixture was then maintained at 20-30 °C and stirred for 6-24 hours. The solid then filtered and dried at 30-50 °C.
  • Polymorphic form C of brequinar sodium salt was prepared according to the following scheme. 360.15 g (0.96 mole) of 6-Flouro-2-(2’-fluoro-l,l’-biphenyl-4-yl)-3-methyl-4- quinolinecarboxylic acid was suspended in 2,541 mL of isopropanol and 79 mL of H2O (97v:3v). 38.80 g (0.97 mole) of sodium hydroxide was added and warmed to 73-77 °C until totally dissolved. The reaction mixture was filtered and then cooled to 57-61 °C, and a seed crystal was added.
  • FIG. 8 is an X-ray powder diffraction (XRPD) pattern of the polymorph C form of brequinar sodium salt prepared according to this method. The method gave an 88.3% yield of a white crystalline solid. The purity was 99.6%, and the water content by KF (w/w) was 5.2%.
  • XRPD X-ray powder diffraction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions contenant une forme cristalline stable de bréquinar et des procédés de fabrication d'une telle composition. L'invention concerne également des procédés d'utilisation de telles compositions pour traiter une affection chez un sujet.
EP21770978.1A 2020-03-20 2021-03-19 Compositions polymorphes stables de bréquinar sodium et procédés d'utilisation et de fabrication de celles-ci Pending EP4121050A4 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062992720P 2020-03-20 2020-03-20
US202063020460P 2020-05-05 2020-05-05
US202063030677P 2020-05-27 2020-05-27
US202063043382P 2020-06-24 2020-06-24
US202063043384P 2020-06-24 2020-06-24
US202063043388P 2020-06-24 2020-06-24
US202063043386P 2020-06-24 2020-06-24
PCT/US2021/023350 WO2021189017A1 (fr) 2020-03-20 2021-03-19 Compositions polymorphes stables de bréquinar sodium et procédés d'utilisation et de fabrication de celles-ci

Publications (2)

Publication Number Publication Date
EP4121050A1 true EP4121050A1 (fr) 2023-01-25
EP4121050A4 EP4121050A4 (fr) 2024-04-17

Family

ID=77771654

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21770978.1A Pending EP4121050A4 (fr) 2020-03-20 2021-03-19 Compositions polymorphes stables de bréquinar sodium et procédés d'utilisation et de fabrication de celles-ci

Country Status (5)

Country Link
EP (1) EP4121050A4 (fr)
JP (1) JP2023518419A (fr)
AU (1) AU2021236757A1 (fr)
CA (1) CA3175964A1 (fr)
WO (1) WO2021189017A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023043830A1 (fr) * 2021-09-15 2023-03-23 Clear Creek Bio, Inc. Polythérapies pour traiter des infections virales

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4655930B2 (ja) * 2003-04-30 2011-03-23 日本新薬株式会社 キノリンカルボン酸誘導体溶媒和物の結晶
US9603804B2 (en) * 2013-04-25 2017-03-28 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
JP6917375B2 (ja) * 2015-09-01 2021-08-11 ザ・ブロード・インスティテュート・インコーポレイテッド 血液がんの治療または予防に有用な化合物および方法
US20190290634A1 (en) * 2018-03-26 2019-09-26 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
KR20210048483A (ko) * 2018-06-22 2021-05-03 오하이오 스테이트 이노베이션 파운데이션 디하이드로오로테이트 데하이드로게나제의 억제 방법 및 조성물

Also Published As

Publication number Publication date
WO2021189017A1 (fr) 2021-09-23
JP2023518419A (ja) 2023-05-01
CA3175964A1 (fr) 2021-09-23
EP4121050A4 (fr) 2024-04-17
AU2021236757A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
AU2018304168B2 (en) Methods of treatment for cystic fibrosis
TWI786110B (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
WO2019018353A1 (fr) Méthodes de traitement de la fibrose kystique
CN110092745B (zh) 一种含芳环的化合物及其应用
US20210300873A1 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN109251212A (zh) 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途
CN100398541C (zh) 嘧啶酮衍生物和3-酮酯
EP2268604A1 (fr) Thérapies contre le cancer utilisant de la lysine substituée isotopiquement
CN105732615A (zh) Cdk激酶抑制剂
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
CN105143208A (zh) 作为激酶抑制剂的喹唑啉
SA06270462B1 (ar) مركبات وطرق لتثبيط التفاعل بين بروتين bcl وشركاء الارتباط
KR102434764B1 (ko) 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용
EP4121050A1 (fr) Compositions polymorphes stables de bréquinar sodium et procédés d'utilisation et de fabrication de celles-ci
CN105820130B (zh) 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
CN109096272B (zh) 一种具有抗肿瘤活性的吲哚异羟肟酸类化合物及其应用
CN108349937A (zh) 二氨基吡啶衍生物
CN104402833B (zh) 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
WO2019149090A1 (fr) Forme cristalline de l'inhibiteur du transporteur 1 d'urate, son procédé de préparation et son utilisation
CN104447583B (zh) 含有环丁烷取代基的吡嗪类化合物及其组合物及用途
CN116284179B (zh) 淫羊藿次苷ii衍生物的制备及应用
WO2024098856A1 (fr) Dérivés anti-virus de la grippe et leur utilisation
CN114105888B (zh) 丙基硫氧嘧啶与具有抗氧化活性的营养素小分子的共晶及其制备方法
CN113825758B (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
TWI769395B (zh) 以吡唑并[3,4-d]嘧啶化合物為有效成分之治療劑

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031450000

Ipc: A61K0031470000

A4 Supplementary search report drawn up and despatched

Effective date: 20240320

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 215/52 20060101ALI20240314BHEP

Ipc: A61K 31/47 20060101AFI20240314BHEP